Skip to main content

Table 3 Estimates of the relative risk of cardiac failure and Excess absolute risk (EAR) (per 10,000 patient-years) of secondary cancer induction estimated with the full model. Results are shown as averages (with uncertainty expressed as 1 standard deviation). The p value is relative to the Wilcoxon signed rank paired test

From: Volumetric modulated arc therapy versus intensity-modulated proton therapy in neoadjuvant irradiation of locally advanced oesophageal cancer

Organ Model Endpoint RA_RP IMPT_2F IMPT_3F P
Whole heart RR CHF 1.7 ± 0.1 1.3 ± 0.1 1.3 ± 0.1 B,C
Left Ventricle RR CHF 1.5 ± 0.1 1.1 ± 0.1 1.1 ± 0.1 B,C
Coronaries RR CAD 1.6 ± 0.4 1.2 ± 0.3 1.2 ± 0.3 A,B,C
Lungs EAR RSCI 19.2 ± 5.7 6.1 ± 2.7 5.7 ± 2.4 A,B,C
  1. RR Relative risk, CAD Coronay artery disease, CHF Chronic heart failure, EAR Excess absolute risk, RSCI Risk of secondary cancer inducton, RA_RP RapidArc Volumetric modulated arc therapy with RapidPlan optimization, IMPT Intensity modulated proton therapy with robust optimization (2 fields: _2F; 3 fields: _3F). Statistical significance: A: IMPT_2F vs IMPT_3F; B: IMPT_2F vs RA_RP; C: IMPT_3F vs RP_RP